Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Sep 6 - Sep 11
Bevacizumab, an anti-VEGF therapy, has been evaluated for its anti-CSC effects in breast cancer (NCT01190345, Phase II)
Select the vial size in mg, enter the bacteriostatic water volume and your required sample size
It may increase the risk of diabetic ketoacidosis in these patients [see Warnings and Precautions (5.1)]
It may be part of care for people with serious liver failure risk after toxic exposure, and it should always be managed by medical professionals
This risk hasnt been confirmed in humans, but the medication isnt recommended for anyone with a personal or family history of medullary thyroid carcinoma
US$ 22.16
US$ 20.84
US$ 22.48
US$ 22.27
US$ 23.01
US$ 24.13
US$ 26.29
US$ 20.10
US$ 26.74
